Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
83.00
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
47
48
Next >
Why Is Cancer Immunotherapy-Focused Compugen Stock Is Trading Higher Today?
December 19, 2023
Gilead Sciences Inc (NASDAQ: GILD) announced an agreement with Compugen Ltd (NASDAQ: CGEN) to license its pre-clinical antibody program against IL-18 binding protein exclusively, including the
Via
Benzinga
Why Is Compugen (CGEN) Stock Up 189% Today?
December 19, 2023
Compugen stock is up on Tuesday as investors in CGEN shares react to an exclusive licensing agreement with Gilead Sciences.
Via
InvestorPlace
These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?
December 18, 2023
2024 is going to be a sizzler in the biopharma sector.
Via
The Motley Fool
Analyzing AstraZeneca In Comparison To Competitors In Pharmaceuticals Industry
December 12, 2023
Via
Benzinga
Health Care Company AstraZeneca Announces Acquisition of Icosavax
December 12, 2023
Via
Benzinga
Oracle's Falling, but You Won't Want to Miss This Soaring Biotech Stock
December 12, 2023
Tuesday brought favorable inflation data, and bullish investors are looking for stock winners.
Via
The Motley Fool
Topics
Economy
Exposures
Interest Rates
Industry Comparison: Evaluating AstraZeneca Against Competitors In Pharmaceuticals Industry
November 27, 2023
Via
Benzinga
Investigating AstraZeneca's Standing In Pharmaceuticals Industry Compared To Competitors
November 13, 2023
Via
Benzinga
Why Is Icosavax (ICVX) Stock Up 46% Today?
December 12, 2023
Icosavax stock is up on Tuesday as investors react to an acquisition deal with AstraZeneca that values ICVX between $15 and $20 per share.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
December 12, 2023
Checking out the biggest pre-market stock movers for Tuesday is the perfect way to get ready for another busy day of trading!
Via
InvestorPlace
AstraZeneca To Acquire US Respiratory Vaccine Player Icosavax For Over $800M
December 12, 2023
AstraZeneca Plc (NASDAQ: AZN) has agreed to acquire Icosavax Inc (NASDAQ: ICVX) at $15.00 per share in cash at closing, plus a non-tradable contingent value right to receive up to $5.00 in cash,...
Via
Benzinga
Neurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Why
December 11, 2023
Pasithea Therapeutics Corp (NASDAQ: KTTA) announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation
Via
Benzinga
AstraZeneca's Investigational Drug Shows Durable Clinical Benefit In Patients With Rare Blood Disease
December 11, 2023
AstraZeneca Plc (NASDAQ: AZN)
Via
Benzinga
AstraZeneca Just Joined the AI Drug Development Craze, but Is It a Buy in 2024?
December 10, 2023
It'll take a few years for its latest moves to pay off, assuming they do.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Is Now the Right Time to Buy AstraZeneca Stock?
December 10, 2023
The pharmaceutical giant is making strident moves to compete in hot markets, but it's not a cheap stock.
Via
The Motley Fool
Pharma Industry on Alert as Biden Administration Explores Patent Seizure Powers
December 07, 2023
The White House is endorsing a contentious power that permits the government to reclaim patents for specific
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
December 04, 2023
AstraZeneca plc (NASDAQ: AZN) has reportedly finalized a partnership deal valued at up to $247 million with Absci Corporation (NASDAQ: ABSI), a U.S.-based firm specializing in artificial intelligence...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
December 02, 2023
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...
Via
Talk Markets
Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers
December 01, 2023
European Medicines Agency (EMA) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's (NYSE: NVO) popular therapies...
Via
Benzinga
AstraZeneca Stops Two Lokelma Late-Stage Trials After Evaluating Potential Benefits
December 01, 2023
AstraZeneca Plc (NASDAQ: AZN) discontinued the STABILIZE-
Via
Benzinga
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston’s Ensem
November 25, 2023
Beijing’s BeiGene acquired global rights to a preclinical novel cyclin-dependent kinase 2 (CDK2) inhibitor from Boston’s Ensem Therapeutics in a $1.3 billion agreement. Ensem will receive an upfront...
Via
Talk Markets
Eli Lilly and Novo Nordisk Are Big Names in Weight Loss, but Investors Shouldn't Count Out This Healthcare Giant
November 22, 2023
Could AstraZeneca be an under-rated buy right now?
Via
The Motley Fool
3 No-Brainer Stocks to Buy With $1,000 Right Now
November 22, 2023
A modest amount of money can go a long way when it's invested in industry-leading businesses with sustained, long-term catalysts.
Via
The Motley Fool
5 Growth Stocks to Buy for 2024
November 20, 2023
Forget the "Magnificent 7." These are the top five growth stocks to buy in the coming year for interested investors.
Via
InvestorPlace
US CDC Rolls Out Additional Doses For Sanofi/AstraZeneca Recently Approved Respiratory Infection Drug As Demand Surges
November 17, 2023
The U.S.
Via
Benzinga
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
November 17, 2023
It might have a hard time finding a home in the market.
Via
The Motley Fool
FDA Approves AstraZeneca's Truqap/Faslodex Combo Therapy For Breast Cancer, Competes With Gilead's Drug
November 17, 2023
FDA approves AstraZeneca Plc's (NASDAQ: AZN) Truqap (capivasertib) in combination with Faslodex (fulvestrant) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative...
Via
Benzinga
Exposures
Product Safety
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small
Via
Benzinga
Exposures
Product Safety
AstraZeneca's Flagship Cancer Drug Imfinzi Fails On Main Goal In Lung Cancer Trial When Combined With Chemoradiotherapy
November 14, 2023
AstraZeneca Plc (NASDAQ: AZN) said its PACIFIC
Via
Benzinga
Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.
November 13, 2023
Choosing dividend aristocrats to buy becomes easy when you elect to buy the royalty of income-generating stocks.
Via
InvestorPlace
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.